Stent-Assisted Coil Embolization for Ruptured Wide-Neck Aneurysms in the Acute Phase of Subarachnoid Hemorrhage: A Single-Center Experience in Japan Authors: Shinju Matsuoka, Yuichiro Tsuji, Hideki Kashiwagi, Akihiro Kambara, Tomohiro Ihata, Yoshiki Fujikawa, Masao Fukumura, Gen Futamura, Ryokichi Yagi, Ryo Hiramatsu, Masahiro Kameda, Naosuke Nonoguchi, Motomasa Furuse, Shinji Kawabata, Toshihiro Takami, Masahiko Wanibuchi Published: 2026 ABSTRACT ObjectiveStent-assisted coil embolization (SAC) has expanded the treatment options for ruptured wide-neck aneurysms; however, SAC during the acute phase of subarachnoid hemorrhage (SAH) remains controversial owing to concerns regarding thromboembolic and hemorrhagic complications. This study aimed to evaluate the feasibility and safety of SAC for ruptured wide-neck aneurysms in the acute phase of SAH at a single center in Japan.MethodsPatients with ruptured wide-neck aneurysms who underwent endovascular treatment within 48 h after SAH onset between January 2015 and December 2024 were retrospectively evaluated. Wide-neck aneurysms were defined as those with a neck width of ≥4 mm or a dome-to-neck ratio of <2. Patients were divided into 2 groups: the SAC group and the non-SAC group. The primary outcome was perioperative complications. Secondary outcomes included angiographic outcomes, clinical outcomes at discharge and 1-year follow-up, and retreatment rates.ResultsA total of 140 patients were included (SAC group, n = 24; non-SAC group, n = 116). Aneurysms in the SAC group demonstrated more complex morphology, particularly lower aneurysm height and smaller dome-to-neck ratios. The rates of perioperative hemorrhagic complications (12.5% vs. 9.4%) and symptomatic thromboembolic complications (8.3% vs. 8.6%) were comparable between the SAC and non-SAC groups. The immediate angiographic outcomes did not differ significantly between the 2 groups. Clinical outcomes at discharge and at 1-year follow-up did not differ significantly.ConclusionSAC for ruptured wide-neck aneurysms in the acute phase of SAH appears to be feasible with no significant differences in perioperative complication rates or clinical outcomes compared with non-SAC treatment. With appropriate patient selection and careful antiplatelet management, SAC may be a reasonable treatment option. Introduction Endovascular coil embolization for ruptured intracranial aneurysms has expanded treatment options with the introduction of the stent-assisted coil embolization (SAC). Although thromboembolic complications associated with stent placement have been a concern, recent studies have demonstrated that advances in endovascular devices and optimized antiplatelet management have resulted in perioperative complication rates comparable to those of coil embolization alone in the treatment of ruptured aneurysms.1–3) In Japan, SAC is an off-label treatment option for ruptured aneurysms. Nevertheless, in real-world clinical practice, stent-assisted treatment is unavoidable for a subset of technically challenging ruptured aneurysms. Recently, relatively favorable outcomes of SAC for ruptured aneurysms have been reported in Japan.4,5) However, evidence regarding SAC in the acute phase of ruptured wide-neck aneurysms in Japan remains limited. Therefore, this study aimed to evaluate real-world clinical outcomes of patients who underwent SAC during the acute phase of subarachnoid hemorrhage (SAH). Materials and Methods This retrospective comparative study was conducted to evaluate the feasibility of SAC in the acute phase of ruptured aneurysms. The study period extended from January 2015 to December 2024 and included consecutive patients who underwent endovascular treatment at our institution. The acute phase was defined as within 48 h after SAH onset. In routine clinical practice, the decision to perform SAC was based on aneurysm morphology, procedural feasibility, and operator judgment rather than neck morphology alone. To establish an appropriate comparator for the SAC group, we retrospectively limited the study population to ruptured aneurysms with unfavorable morphology treated during the acute phase, primarily wide-neck aneurysms, because these lesions were considered most comparable in terms of procedural complexity and treatment strategy. Dissecting and fusiform aneurysms were also included because they frequently present similar technical challenges and may require adjunctive techniques such as SAC. The indication for SAC was determined by consensus of at least 2 board-certified neurointerventionists, either prospectively based on preprocedural imaging findings or intraoperatively according to technical feasibility. SAC was considered when adjunctive techniques were deemed necessary to achieve safe and effective treatment, particularly in technically challenging lesions requiring parent artery preservation, including wide-neck, dissecting, or fusiform aneurysms. This study was approved by the Institutional Review Board of Osaka Medical and Pharmaceutical University (approval number: 2840-3). The off-label use of intracranial stents in the acute phase was carefully reviewed and approved by the Institutional Ethics Committee of Osaka Medical and Pharmaceutical University Hospital (approval number: 2024-381). The requirement for written informed consent was waived because of the retrospective study design. The primary outcome of this study was the rate of perioperative complications occurring within 30 days after the procedure, including hemorrhagic and symptomatic thromboembolic events. Secondary outcomes included immediate angiographic results, clinical outcomes at discharge and 1-year follow-up, and retreatment rates. A wide-neck aneurysm was defined as a neck width of ≥4 mm or a dome-to-neck ratio of <2.6) Patients who underwent parent artery occlusion were excluded from the analysis. Clinical data, including baseline demographics, World Federation of Neurosurgical Societies (WFNS) grading scale, aneurysm morphological parameters, procedural complications, and clinical outcomes, were retrospectively obtained from medical records. Aneurysm size, neck width, and height were measured using 3D rotational angiography. The degree of aneurysm occlusion was classified as complete occlusion (CO), neck remnant (NR), or body filling. All endovascular procedures were performed using a transfemoral approach under general anesthesia. Systemic heparinization was administered to maintain an activated clotting time (ACT) of ≥250 s. The following stents were used: Neuroform Atlas (Stryker, Kalamazoo, MI, USA), Low-profile Visualized Intraluminal Support (LVIS) Blue (Terumo Neuro, Aliso Viejo, CA, USA), and LVIS Jr (Terumo Neuro). Once the decision to deploy a stent was made intraoperatively, a loading dose of dual antiplatelet therapy (DAPT) was administered through a nasogastric tube. In the early period, patients received aspirin 300 mg and clopidogrel 300 mg. In the later period, after intravenous administration of ozagrel sodium, aspirin 300 mg and prasugrel 20 mg were administered to achieve an immediate and more reliable antiplatelet effect. The choice of antiplatelet agents was based on the institutional protocol at the time of treatment. Routine reversal of systemic heparinization was not performed after treatment completion unless clinically indicated. Postoperative platelet function testing was not routinely performed. DAPT was continued from the day after the procedure for at least 3 months, followed by single antiplatelet therapy. The off-label use of stents was fully explained to the patients or their families, and consent was obtained whenever feasible. Perioperative complications were classified as ischemic or hemorrhagic events. Ischemic complications were defined as thromboembolic events, whereas hemorrhagic complications included procedure-related intracranial hemorrhages defined as intraoperative aneurysm rupture, postoperative re-rupture, or expansion of intracerebral hemorrhage. Continuous variables are presented as medians with interquartile ranges and were compared using the Mann–Whitney U-test. Categorical variables were compared using the chi-squared test or Fisher’s exact test, as appropriate. All statistical tests were 2-sided, and a P-value <0.05 was considered statistically significant. Statistical analyses were performed using JMP version 17.0 (SAS Institute, Cary, NC, USA). Results During the study period, 216 patients with ruptured aneurysms underwent endovascular treatment at our institution. Of these, 140 ruptured wide-neck aneurysms were included in this analysis, with 24 patients in the SAC group and 116 patients in the non-SAC group. Seventy-six patients were excluded for the following reasons: non-wide-neck aneurysms (n = 65) and parent artery occlusion (n = 11) (Fig. 1). Flow diagram of this study. SAC, stent-assisted coil embolization The baseline patient characteristics are summarized in Table 1. The median age of patients in the SAC group was 64.5 years, and 10 patients (41.6%) presented with a severe clinical grade (WFNS grade IV or V). The aneurysm morphological parameters differed between the 2 groups, with the SAC group showing a significantly lower height (2.8 vs. 3.9 mm, P = 0.006) and dome-to-neck ratio (1.13 vs. 1.46, P = 0.001). No significant differences were observed between the 2 groups in terms of baseline characteristics, including age, sex, WFNS grade, or aneurysm location. The stents used in the SAC group included the Neuroform Atlas (Stryker; n = 12), LVIS Blue (Terumo Neuro; n = 9), and LVIS Jr (Terumo Neuro; n = 3). In the non-SAC group, the treatment techniques included simple coiling (n = 54, 46.6%), balloon-assisted coiling (n = 28, 24.1%), and double-catheter coiling (n = 34, 29.3%) (Table 2). CO was achieved in 54.2% of the SAC group and 51.7% of the non-SAC group, whereas NR occurred in 33.3% and 40.5%, respectively (P = 0.62). Table 1Patient and aneurysm characteristics of the SAC and non-SAC groupsVariablesSAC (n = 24)Non-SAC (n = 116)P-valueAge (years), median (IQR)64.5 (50.0–81.5)64.0 (54.0–77.0)0.64Female, n (%)18 (75.0)90 (77.6)0.79WFNS grade IV–V, n (%)10 (41.6)42 (36.2)0.65Aneurysm location, n (%)0.31 ICA12 (50.0)39 (33.6) ACA7 (29.2)35 (30.2) MCA1 (4.1)23 (19.8) VBA4 (16.7)17 (14.7) Other0 (0)2 (1.7)Aneurysm type, n (%)<0.001 Saccular15 (62.5)116 (100) Dissecting/fusiform9 (37.5)0 (0)Aneurysm morphology Maximum dome size (mm), median (IQR)3.8 (2.5–6.1)4.7 (3.3–6.2)0.13 Neck diameter (mm), median (IQR)3.2 (2.2–5.0)3.3 (2.3–4.3)0.73 Height (mm), median (IQR)2.8 (1.9–3.5)3.9 (3.0–5.6)0.006 Dome-to-neck ratio, median (IQR)1.13 (0.92–1.34)1.46 (1.27–1.67)0.001ACA, anterior cerebral artery; ICA, internal carotid artery; IQR, interquartile range; MCA, middle cerebral artery; SAC, stent-assisted coil embolization; VBA, vertebrobasilar artery; WFNS, World Federation of Neurosurgical Societies Patient and aneurysm characteristics of the SAC and non-SAC groups ACA, anterior cerebral artery; ICA, internal carotid artery; IQR, interquartile range; MCA, middle cerebral artery; SAC, stent-assisted coil embolization; VBA, vertebrobasilar artery; WFNS, World Federation of Neurosurgical Societies Table 2Procedure details, angiographic results, and complications of the SAC and non-SAC groupsVariablesSAC (n = 24)Non-SAC (n = 116)P-valueTreatment technique, n (%)<0.001 SAC24 (100.0)0 (0) Simple coiling0 (0)54 (46.6) Balloon-assisted coiling0 (0)28 (24.1) Double-catheter coiling0 (0)34 (29.3)Immediate angiographic outcomes, n (%)0.62 Complete obliteration13 (54.2)60 (51.7) Neck remnant8 (33.3)47 (40.5) Body filling3 (12.5)9 (7.8)Any complication, n (%)5 (20.8)21 (18.1)0.78Hemorrhagic complications, n (%)3 (12.5)11 (9.4)0.70 Intraoperative rupture3 (12.5)5 (4.3)0.13 Postoperative re-rupture0 (0)2 (1.7)1 Expansion of intracerebral hemorrhage0 (0)4 (3.4)1Ischemic complications, n (%)2 (8.3)10 (8.6)0.96SAC, stent-assisted coil embolization Procedure details, angiographic results, and complications of the SAC and non-SAC groups SAC, stent-assisted coil embolization In the SAC group, there were 3 hemorrhagic complications, all of which were intraoperative aneurysm ruptures associated with coil manipulation. These complication rates did not significantly differ between the early and late study periods (1/12 [8.3 %] vs. 2/12 [16.7%], respectively). In contrast, hemorrhagic complications in the non-SAC group included 5 intraoperative ruptures, 2 postoperative re-ruptures, and 4 cases of expansion of intracerebral hemorrhage around the ruptured aneurysm. Hemorrhagic complication rates were comparable between the groups (SAC: 12.5% vs. non-SAC: 9.4%, P = 0.70), but the incidence of intraoperative rupture was higher in the SAC group (SAC group: 12.5% vs. non-SAC group: 4.3%, P = 0.13) (Table 2). After excluding dissecting and fusiform aneurysms, the intraprocedural rupture rate in saccular aneurysms treated with SAC was 6.6%, with no significant difference compared with the non-SAC group (P = 0.52). Of the 3 cases in the SAC group that experienced intraoperative rupture, 1 had a modified Rankin Scale (mRS) score of 0 and the other had an mRS score of 2 at 3 months; both had favorable clinical outcomes. The remaining case had a poor outcome, with an mRS score of 5 at 3 months; however, this was a severe case of SAH, with a WFNS grade of 5. No hemorrhagic events related to external ventricular or spinal drainage, expansion of intracerebral hemorrhage, or systemic bleeding such as gastrointestinal hemorrhage were observed during the acute phase. No cases resulted in significant clinical deterioration attributable to hemorrhage complications. Symptomatic thromboembolic complication rates were also similar (SAC: 8.3% vs. non-SAC: 8.6%, P = 0.96) (Table 2). In the SAC group, no cases of intraoperative stent thrombosis or postoperative stent occlusion were observed. Two ischemic complications were identified, both of which were distal embolic events in the territory of the deployed stent. One of these cases (4.1%) resulted in clinical deterioration, whereas the other did not affect the clinical outcome. By contrast, ischemic complications affecting clinical outcomes occurred in 4 cases (3.4%) in the non-SAC group. Three of the 4 clinically significant ischemic complications in the non-SAC group occurred in middle cerebral artery bifurcation aneurysms and resulted in M2 territory ischemia. There were no significant differences in clinical outcomes at discharge or at the 1-year follow-up. Follow-up data at 1 year were available in 20 of 24 patients (83.3%) in the SAC group and 103 of 116 patients (88.8%) in the non-SAC group. Retreatment for aneurysm recurrence was required in 1 of 20 patients (5.0%) in the SAC group and 19 of 103 patients (18.4%) in the non-SAC group (P = 0.13) (Table 3). Table 3Clinical outcomes at discharge and 1 year in the SAC and non-SAC groupsVariablesSAC (n = 24)Non-SAC (n = 116)P-valueClinical outcome at discharge, n (%)0.59 mRS 0–210/24 (41.7)60/116 (51.7) mRS 3–512/24 (50.0)46/116 (39.7) mRS 62/24 (8.3)10/116 (8.6)Clinical outcome at 1 year, n (%)0.74 mRS 0–211/20 (55.0)63/103 (61.2) mRS 3–55/20 (25.0)26/103 (25.2) mRS 64/20 (20.0)14/103 (13.6)Retreatment, n (%)1/20 (5.0)19/103 (18.4)0.13Follow-up clinical data at 1 year were available for 20 of 24 patients in the SAC group and 103 of 116 patients in the non-SAC group.mRS, modified Rankin Scale; SAC, stent-assisted coil embolization Clinical outcomes at discharge and 1 year in the SAC and non-SAC groups Follow-up clinical data at 1 year were available for 20 of 24 patients in the SAC group and 103 of 116 patients in the non-SAC group. mRS, modified Rankin Scale; SAC, stent-assisted coil embolization The LVIS/LVIS Jr group had a significantly lower dome-to-neck ratio than the Neuroform Atlas group (1.08 vs. 1.26, P = 0.03); however, complication rates did not differ significantly between the stent types (Table 4). Table 4Comparison between LVIS/LVIS Jr and Neuroform Atlas stentsVariablesLVIS/LVIS Jr. (n = 12)Neuroform Atlas (n = 12)P-valueAge (years), median (IQR)63.5 (50.0–80.0)67.0 (52.0–81.5)0.77WFNS grade IV–V, n (%)7 (58.4)3 (25.0)0.21Aneurysm location, n (%)<0.01 ICA8 (66.7)4 (33.3) ACA0 (0)7 (58.4) MCA0 (0)1 (8.3) VBA4 (33.3)0 (0)Maximum dome size (mm), median (IQR)3.1 (1.6–5.5)3.8 (2.8–6.2)0.50Height (mm), median (IQR)2.7 (1.4–3.3)2.9 (2.1–4.8)0.17Dome-to-neck ratio, median (IQR)1.08 (0.75–1.20)1.26 (1.03–1.55)0.03Immediate angiographic outcome, n (%)0.46 Complete obliteration5 (41.7)8 (66.7) Neck remnant5 (41.7)3 (25.0) Body filling2 (16.6)1 (8.3)Hemorrhagic complications, n (%)2 (16.6)1 (8.3)0.53Ischemic complications, n (%)2 (16.6)0 (0)0.47Clinical outcome at discharge, n (%)0.69 mRS 0–24 (33.3)6 (50.0) mRS 3–57 (58.4)5 (41.7) mRS 61 (8.3)1 (8.3)Retreatment, n (%)1 (8.3)0 (0)1.0ACA, anterior cerebral artery; ICA, internal carotid artery; IQR, interquartile range; LVIS, Low-profile Visualized Intraluminal Support, Terumo Neuro, Aliso Viejo, CA, USA; LVIS Jr., Terumo Neuro; MCA, middle cerebral artery; mRS, modified Rankin Scale; Neuroform Atlas, Stryker, Kalamazoo, MI, USA; VBA, vertebrobasilar artery; WFNS, World Federation of Neurosurgical Societies Comparison between LVIS/LVIS Jr and Neuroform Atlas stents ACA, anterior cerebral artery; ICA, internal carotid artery; IQR, interquartile range; LVIS, Low-profile Visualized Intraluminal Support, Terumo Neuro, Aliso Viejo, CA, USA; LVIS Jr., Terumo Neuro; MCA, middle cerebral artery; mRS, modified Rankin Scale; Neuroform Atlas, Stryker, Kalamazoo, MI, USA; VBA, vertebrobasilar artery; WFNS, World Federation of Neurosurgical Societies Case presentations Case 1 A 66-year-old woman presented with WFNS grade II SAH. No ruptured aneurysm was identified on the initial DSA performed on admission. However, follow-up DSA on the next day revealed a blood blister–like aneurysm on the anterior wall of the left internal carotid artery. After administration of aspirin 300 mg and prasugrel 20 mg, SAC was performed using a 4.0 × 22-mm LVIS stent. After 3 months of rehabilitation, the patient was discharged with an mRS score of 2. No recurrence was observed at the 1-year follow-up (Fig. 2). (A) Plain CT of the brain showing subarachnoid hemorrhage. (B, C) 3D-DSA (B) and DSA (C) showing a blood blister–like aneurysm on the anterior wall of the left ICA. (D) Coil embolization with an LVIS stent was performed. (E) Cone-beam CT after SAC. (F) After SAC of the left ICA, DSA demonstrated occlusion of the aneurysmal dilation. ICA, internal carotid artery; LVIS, Low-profile Visualized Intraluminal Support, Terumo Neuro, Aliso Viejo, CA, USA; SAC, stent-assisted coil embolization Case 2 An 84-year-old woman presented with WFNS grade III SAH. DSA revealed a small ruptured anterior communicating artery aneurysm (height, 2.46 mm and neck diameter, 2.86 mm). After aspirin 300 mg and prasugrel 20 mg were administered, SAC was performed using a 3 × 21-mm Neuroform Atlas stent. The occlusion status was complete obliteration and the patient was transferred to a rehabilitation hospital with an mRS score of 4 at discharge (Fig. 3). (A) CT of the brain showing subarachnoid hemorrhage. (B, C) 3D-DSA (B) and DSA (C) demonstrating a ruptured anterior communicating artery aneurysm (working projection). (D) Coil embolization with a Neuroform Atlas was performed. (E) Cone-beam CT after SAC. (F) Final angiogram showing adequate embolization of the aneurysm with preservation of the parent vessels. Neuroform Atlas, Stryker, Kalamazoo, MI, USA; SAC, stent-assisted coil embolization Case 3 A 72-year-old patient presented with WFNS grade V SAH caused by a ruptured thrombosed right vertebral artery aneurysm. DSA showed a hypoplastic left vertebral artery. Following loading doses of aspirin 300 mg and prasugrel 20 mg, SAC was performed using a 4.5 × 23-mm LVIS stent. During deployment of the first coil and stent, an intraprocedural rupture occurred. Systemic heparinization was not reversed with protamine. Instead, the blood pressure was lowered promptly, and coil embolization was continued through the jailed microcatheter. Additional coils were rapidly deployed to achieve hemostasis, and final angiography demonstrated CO after total coil deployment. The patient was discharged with an mRS score of 4. At 12 months follow-up, CO was confirmed (Fig. 4). (A) Initial brain CT showing a thick subarachnoid hemorrhage in the posterior cranial fossa. (B) DSA demonstrating a ruptured thrombosed right vertebral artery aneurysm and a hypoplastic left vertebral artery. (C) 3D-DSA showing the thrombosed right vertebral artery aneurysm (working projection). (D) Intraprocedural aneurysm rupture occurring during deployment of the first coil and stent. Hemostasis was rapidly achieved by blood pressure reduction and continued coil packing through the jailed microcatheter. (E) SAC using an LVIS stent. (F) Final angiogram demonstrating complete occlusion with preservation of the parent artery. LVIS, Low-profile Visualized Intraluminal Support, Terumo Neuro, Aliso Viejo, CA, USA; SAC, stent-assisted coil embolization Discussion At our institution, coil embolization using the double-catheter technique has been actively employed as the primary endovascular strategy for the treatment of ruptured wide-neck aneurysms. However, some aneurysms are technically challenging using this method. In such cases, SAC is selectively used when conventional techniques are considered technically difficult or insufficient to achieve stable coil embolization while preserving the parent artery, particularly in aneurysms with a dome-to-neck ratio close to 1.0 and a dome height nearly equal to the neck width, as well as in blister-like or dissecting aneurysms, after obtaining approval from the institutional ethics committee. The present study provides important real-world evidence in Japan, where SAC for ruptured aneurysms remains off-label. Although the usefulness of the Woven EndoBridge device (WEB; Terumo Neuro) for ruptured aneurysms has been reported, treatment using the WEB has not been adopted for SAH at our institution.7,8) In this study, the acute phase was defined as within 48 h after SAH onset because early aneurysm treatment is recommended to prevent rebleeding and reflects real-world clinical practice at our institution. In this single-center cohort study, SAC for ruptured wide-neck aneurysms in the acute phase was found to be feasible. Despite the unfavorable aneurysm morphology in the SAC group, there were no differences between the 2 groups in terms of the immediate angiographic results, perioperative complication rates, and clinical outcomes. There was no significant difference in the rates of hemorrhagic and thromboembolic complications of ruptured aneurysms between the SAC and non-SAC groups in a systematic review published in 2019.9) However, recent studies have reported a decline in complication rates. In 2020, Xue et al. reported a propensity score–matched analysis comparing LVIS-assisted coiling with coiling alone, showing no significant differences in overall complications, including hemorrhagic and ischemic events.1) Yi et al. reported that procedure-related complication rates did not differ between SAC using the Neuroform Atlas (Stryker) and coiling alone in 2023.10) In stent-specific analyses, LVIS stents (Terumo Neuro) were associated with higher rates of in-stent thrombosis and postoperative cerebral infarction than Neuroform Atlas stents.10) In the review, there was no significant difference in favorable clinical outcomes between the SAC and non-SAC groups, whereas the recurrence rate was significantly lower in the SAC group.9) Xue et al. and Yi et al. also reported higher CO rates on follow-up angiography and lower retreatment rates in the SAC group.1,10) Consistent with these previous studies, our results showed no significant difference in immediate postprocedural occlusion status and no differences in clinical outcomes at discharge or at the 1-year follow-up between the SAC and non-SAC groups. Although the retreatment rate tended to be lower in the SAC group, the difference was not statistically significant, possibly due to the small sample size. The antiplatelet regimen, including the choice of agent and the timing of administration, is a critical factor that may influence the treatment outcomes of SAC in the acute phase of SAH. Although the preoperative administration of antiplatelet agents has been reported to be desirable for the prevention of ischemic complications,11) the specific regimen and timing vary considerably among institutions. At our institution, in the later period, ozagrel sodium is administered intraoperatively, particularly before stent deployment, followed by loading doses of aspirin 300 mg and prasugrel 20 mg, after which stent placement is performed. Because oral antiplatelet agents administered via a nasogastric tube may require time to achieve adequate platelet inhibition, intravenous ozagrel sodium was administered simultaneously to obtain an immediate antiplatelet effect during the procedure. Ozagrel, a thromboxane A2 synthase inhibitor, has rapid antiplatelet and vasodilatory effects and has been reported to be useful during SAC in the acute phase of ruptured aneurysms.12) This strategy was intended to bridge the period until the full antiplatelet effect of oral DAPT was achieved. Additionally, clopidogrel resistance has been reported to increase the risk of thromboembolic complications during neurointervention procedures.13) Therefore, the P2Y12 inhibitor was changed from clopidogrel to prasugrel during the later study period to achieve more reliable platelet inhibition. In the present study, no significant differences were observed in the hemorrhagic or symptomatic thromboembolic complications between the SAC and non-SAC groups. Importantly, no stent thrombosis or occlusion was observed, suggesting that the antiplatelet management strategy was effective in preventing thrombotic complications. Furthermore, although the number of cases was limited, there were no differences in complication rates between the Neuroform Atlas and LVIS stent groups. In some countries, the intraoperative use of glycoprotein IIb/IIIa inhibitors such as tirofiban allows for delayed initiation of DAPT after the procedure.14,15) However, tirofiban is not approved for use in Japan; therefore, DAPT should be administered before stent deployment. Previous studies based on Japanese registry results have reported an intraoperative rupture rate of 4.1% for ruptured cerebral aneurysms.16) However, Brinjikji et al. found that the risk of rupture during endovascular treatment was higher for small aneurysms (less than 3 mm), at 8.3%.17) Imamura et al. also identified small aneurysms (less than 5 mm) and branched aneurysms as predictors of intraoperative rupture.16) Furthermore, recent reports show that the intraoperative rupture rate for ruptured micro-cerebral aneurysms in SAC ranges from 2.2% to 5.4%.18,19) The relatively high intraoperative rupture rate of 12.5% observed in the SAC group in this study is a significant concern. This may reflect the fact that aneurysms in the SAC group were characterized by a smaller size and lower dome-to-neck ratio than those in the non-SAC group. In addition, SAC could restrict the kickback of the jailed microcatheter and may have increased the risk of coil perforation during the procedure. Furthermore, the SAC group included dissecting aneurysms and fusiform aneurysms. Importantly, after exclusion of dissecting and fusiform aneurysms, the intraprocedural rupture rate among saccular aneurysms treated with SAC was comparable to that of the non-SAC group. This finding suggests that the relatively higher rupture rate observed in the overall SAC cohort may be attributable, at least in part, to the intrinsic fragility of dissecting and fusiform lesions rather than the procedural risk of SAC itself. DAPT is essential to prevent stent thrombosis and postoperative ischemic complications when performing SAC. However, it may increase the risk of hemorrhagic complications by impairing hemostasis during the management of intraprocedural rupture and additional invasive procedures. Therefore, the higher hemorrhagic complication rate observed in the SAC group may reflect not only the complexity of aneurysm morphology but also the unavoidable pharmacological burden associated with antiplatelet therapy. This inherent dilemma should be considered when interpreting the safety profile of SAC in the acute phase of ruptured aneurysms. The outcome of treatment for a ruptured aneurysm depends on several factors, including the severity of the initial bleeding, the patient’s condition, the characteristics of the aneurysm and any complications. Compared to previous studies, our SAC cohort included a relatively high proportion of severe cases (WFNS grades IV–V, 41.6%) and older patients.1,9,10,20,21) Considering these unfavorable baseline characteristics, the proportion of favorable outcomes observed in this study was acceptable. However, the outcomes observed in this study should be interpreted with caution. SAC for ruptured aneurysms may offer several advantages. First, the use of LVIS stents enables treatment of dissecting aneurysms, providing a potential flow-diverting effect in addition to coil embolization. Second, stent deployment expands the treatment options for wide-neck aneurysms, which are difficult to manage using conventional techniques. Third, stent assistance for aneurysms with blebs located near the neck may prevent re-rupture while preserving the parent artery. This study had several limitations. First, this was a single-center, retrospective study, and treatment allocation was not randomized. SAC was selectively performed in technically challenging aneurysms; therefore, the comparison between groups may have been affected by selection bias. Second, the cohort included a relatively high proportion of severely affected patients, which limited long-term follow-up in some cases. This may have affected the assessment of recurrence and retreatment rates. Third, the sample size of the SAC group was relatively small, which may have limited statistical power. Finally, the antiplatelet regimens were not standardized throughout the study period, which may have influenced the perioperative complication rates. Conclusion This single-center retrospective study suggested that SAC for ruptured wide-neck aneurysms is feasible even for morphologically complex aneurysms. SAC did not show any difference in perioperative complication rates or clinical outcomes compared with non-SAC treatment. With appropriate patient selection and careful antiplatelet management, SAC for ruptured aneurysms may be a reasonable treatment option.